Fatma Ceyda Korucu a,*, Ece Senyigit b , Osman Kostek c , Nazım Can Demircan c , Bulent Erdogan c , Sernaz Uzunoglu c , Irfan Cicin c
a Trakya University Health Center for Medical Research and Practice, Edirne, Turkey
b Faculty of Medicine, Trakya University, Turkey
c Department of Medical Oncology, Faculty of Medicine, Trakya University, Turkey
Doi: 10.1016/j.jons.2018.06.001 - Article's Language: EN
Journal of Oncological Sciences 4 (2018) 80-84
Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54e68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5e10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue.
Keywords: Cancer patients; Oncology;Polypharmacy; Drug interaction; Chemotherapy